Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

OSAKA, Japan, and CAMBRIDGE, Massachusetts, March 13, 2024– Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials